Very clever.
The SurgCentre sites become the clinical trial sites for the next CLBP trial. The sites generate extra volume from the trial participants and with a little bit of cream of the top for trial costs it may even be a net earner.
MSB move away from the treatment as a restorative or replacement disc therapy which requires improvement on both pain and function. So earlier stage of problems where pain reduction on its own can become the primary endpoint; naturally at much lower pricing to be cost-effective.
CHF is put out as a partnering opportunity. MSB can battle it with the FDA over agvd.
It is very creative – and SI is certainly not just a pretty face.
Ann: Mesoblast Raises US$110M Led By US Strategic Investor Group, page-85
-
- There are more pages in this discussion • 424 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.5¢ |
Change
-0.020(2.01%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 97.5¢ | $596.4K | 603.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 28620 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 49813 | 27 |
View Market Depth
| Last trade - 11.09am 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |